Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of $663.55 million. The enterprise value is $677.09 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 669.05 million shares outstanding. The number of shares has increased by 2.22% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 669.05M |
| Shares Change (YoY) | +2.22% |
| Shares Change (QoQ) | -9.59% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 669.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.07 |
| Forward PS | 2.00 |
| PB Ratio | 3.08 |
| P/TBV Ratio | 8.83 |
| P/FCF Ratio | 130.31 |
| P/OCF Ratio | 109.06 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 73.98, with an EV/FCF ratio of 132.97.
| EV / Earnings | n/a |
| EV / Sales | 2.11 |
| EV / EBITDA | 73.98 |
| EV / EBIT | 119.33 |
| EV / FCF | 132.97 |
Financial Position
The company has a current ratio of 2.76, with a Debt / Equity ratio of 0.55.
| Current Ratio | 2.76 |
| Quick Ratio | 2.00 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | 13.02 |
| Debt / FCF | 23.40 |
| Interest Coverage | 0.46 |
Financial Efficiency
Return on equity (ROE) is -6.78% and return on invested capital (ROIC) is 1.00%.
| Return on Equity (ROE) | -6.78% |
| Return on Assets (ROA) | 0.84% |
| Return on Invested Capital (ROIC) | 1.00% |
| Return on Capital Employed (ROCE) | 1.74% |
| Revenue Per Employee | $793,832 |
| Profits Per Employee | -$34,931 |
| Employee Count | 404 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 0.61 |
Taxes
In the past 12 months, Pharming Group has paid $10.63 million in taxes.
| Income Tax | 10.63M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.92% in the last 52 weeks. The beta is 0.44, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | -2.92% |
| 50-Day Moving Average | 8.57 |
| 200-Day Moving Average | 8.47 |
| Relative Strength Index (RSI) | 64.50 |
| Average Volume (20 Days) | 2,992 |
Short Selling Information
| Short Interest | 1,622 |
| Short Previous Month | 1,582 |
| Short % of Shares Out | 0.00% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | 0.32 |
Income Statement
In the last 12 months, Pharming Group had revenue of $320.71 million and -$14.11 million in losses. Loss per share was -$0.02.
| Revenue | 320.71M |
| Gross Profit | 285.37M |
| Operating Income | 5.67M |
| Pretax Income | -15.41M |
| Net Income | -14.11M |
| EBITDA | 9.15M |
| EBIT | 5.67M |
| Loss Per Share | -$0.02 |
Full Income StatementBalance Sheet
The company has $107.27 million in cash and $119.14 million in debt, giving a net cash position of -$11.87 million or -$0.02 per share.
| Cash & Cash Equivalents | 107.27M |
| Total Debt | 119.14M |
| Net Cash | -11.87M |
| Net Cash Per Share | -$0.02 |
| Equity (Book Value) | 215.29M |
| Book Value Per Share | 0.32 |
| Working Capital | 136.57M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $6.08 million and capital expenditures -$992,000, giving a free cash flow of $5.09 million.
| Operating Cash Flow | 6.08M |
| Capital Expenditures | -992,000 |
| Free Cash Flow | 5.09M |
| FCF Per Share | $0.01 |
Full Cash Flow StatementMargins
Gross margin is 88.98%, with operating and profit margins of 1.77% and -4.40%.
| Gross Margin | 88.98% |
| Operating Margin | 1.77% |
| Pretax Margin | -1.14% |
| Profit Margin | -4.40% |
| EBITDA Margin | 2.85% |
| EBIT Margin | 1.77% |
| FCF Margin | 1.59% |